Our findings highlight the immune-editing role of stress-programmed Effector regulatory T cells, Neoadjuvant chemotherapy, Stress-programmed immune states, TNF α -TNFR2 axis, breast cancercell states and support their therapeutic potential as a rational target in breast cancer. Here, TNFRSF1B is linked to breast carcinoma.